GPBAR1 and neoplasm: In a murine model of tumor growth, the administration of a TGR5 agonist (INT777) or the administration of UDCA inhibited the activation of Tregs through the TGR5-AMPK-PKA (AMP-kinase, protein kinase A) axis.31 These findings underscore the involvement of TGR5 in regulating immune responses that may be relevant to the development of HCC.31